At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 97 enrolled
Drug / intervention
AXS-05 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Active-Controlled Trial of AXS-05 Administered Orally to Subjects With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating AXS-05 and Bupropion for Major Depressive Disorder. Completed, enrolled 97 participants across 4 sites.
Detailed Summary
Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedJul 2018
Primary CompletionJan 2019
TodayJul 2026
First PostedJul 23, 2018
Enrollment StartMay 30, 2018
Primary CompletionJan 7, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.9 years ago
Interventions
AXS-05drug
AXS-05 taken twice daily for 6 weeks.
Bupropiondrug
Bupropion taken twice daily for 6 weeks.